SHL Telemedicine closes second capital increase Mittwoch, 17. Februar 2021 - 18:00

Press release

Tel Aviv / Zurich, February 17, 2021 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, has announced that it has issued 2,288,889 new ordinary shares from its authorized capital today (the "New Shares"). The New Shares will be listed on SIX Swiss Exchange on February 18, 2021.

Following this issuance, the number of SHL shares issued increases by 18.79% from 12,178,491 to 14,467,380. In addition, 1,144,444 options have been granted on February 17, 2021 to purchase further ordinary shares of the Company to be newly issued from the authorized capital upon exercise (ratio 1:1, exercise price CHF 11.00, exercise period 24 months). The New Shares have been placed by way of a private placement. The issue price for each New Share is CHF 9.00. No subscription rights of the existing shareholders apply and no public offering takes place. Pursuant to the Swiss Financial Services Act, a listing prospectus has been issued by SHL and approved by SIX Exchange Regulation for the purpose of the listing of the New Shares.

Today’s share issuance is the second of two capital increases as announced on December 17, 2020.

SHL’s share capital before and after the second capital increase and placement:

This notice does not contain or constitute an offer, solicitation of an offer or prospectus.

According to SHL’s early preliminary estimation at the time of the closing of this second capital increase, its total equity as of December 31, 2020 may amount to USD 36.1 million which reflects a minor increase of USD 1.4 million in fiscal year 2020 fully attributed to foreign currency effects. Therefore, no material change in the total capitalization of SHL is expected for the respective financial year. This preliminary information has neither been reviewed nor audited by the Company’s auditors and should be considered as subject to change and shall be superseded in its entirety by the Company’s upcoming audited consolidated financial statements for the year ended December 31, 2020.

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.